| 55.93 0.13 (0.23%) | 10-23 11:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 74.7 |
1-year : | 87.25 |
| Resists | First : | 63.95 |
Second : | 74.7 |
| Pivot price | 58.33 |
|||
| Supports | First : | 54.03 |
Second : | 47.9 |
| MAs | MA(5) : | 58.12 |
MA(20) : | 57.85 |
| MA(100) : | 47.52 |
MA(250) : | 41.25 |
|
| MACD | MACD : | 2.1 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 39.6 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 63.95 | Low : | 19.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KYMR ] has closed above bottom band by 21.8%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 59.3 - 59.64 | 59.64 - 60.01 |
| Low: | 54.37 - 54.72 | 54.72 - 55.11 |
| Close: | 55.12 - 55.75 | 55.75 - 56.42 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Wed, 22 Oct 2025
BTIG Maintains 'Buy' Rating on KYMR, Raises Price Target to $75 - GuruFocus
Wed, 22 Oct 2025
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Tue, 21 Oct 2025
Kymera Therapeutics (KYMR) Receives New "Outperform" Rating from Mizuho | KYMR Stock News - GuruFocus
Tue, 21 Oct 2025
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Exploring a Compelling 10.27% Potential Upside - DirectorsTalk Interviews
Fri, 17 Oct 2025
Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Maint - GuruFocus
Mon, 13 Oct 2025
Kymera Therapeutics stock hits 52-week high at 59.03 USD - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 111.5 (%) |
| Shares Short | 8,090 (K) |
| Shares Short P.Month | 8,160 (K) |
| EPS | -3.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.77 |
| Profit Margin | 0 % |
| Operating Margin | -736.9 % |
| Return on Assets (ttm) | -20 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | -55.3 % |
| Gross Profit (p.s.) | -3.45 |
| Sales Per Share | 0.62 |
| EBITDA (p.s.) | -4.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -251 (M) |
| Levered Free Cash Flow | -154 (M) |
| PE Ratio | -16.1 |
| PEG Ratio | 0 |
| Price to Book value | 4.07 |
| Price to Sales | 89.81 |
| Price to Cash Flow | -16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|